Method To Prevent Biofilm Formation in Various Clinical Settings (Contact Lenses, Wounds, Cystic Fibrosis, Etc.)

Tech ID: 04-08

Researchers at National Jewish Health have determined that actin originating from necrotized human neutrophils serve as a biological matrix in the formation of microbial biofilms in the airways of cystic fibrosis (CF) patients.  Since biofilm formation allows for the survival of microbial organisms in the airways of CF patients and is also associated with increased morbidity and mortality, targeting actin and/or neutrophils could be the basis for the development of a potential therapy for CF.

Potential Application

  • Targeted therapy for preventing or reducing biofilm formation in cystic fibrosis and in other diseases such as infectious kidney stones, cystitis, dental caries, chronic otitis media, bacterial endocarditis, osteomyelitis, wounds (usually burns), and acne.
  • Prevention of microbial biofilm development on orthopedic implants, stents, catheters and other medical devices.
  • An assay to test compounds for their ability to prevent/reduce biofilm formation by assessing the ability of microbial organisms to bind to actin.

Advantages of Invention
This therapy, focused on biofilm prevention or degradation, is particularly applicable for early stage CF in young patients when antimicrobial agents are only partially effective at best.

State of Development
Our scientists have shown the following in vitro :

  • Biofilm development of P. aeruginosa is enhanced with:
    - the addition of human viable neutrophils and correlates with an increase in the number of necrotic neutrophils. 
    - the addition of neutrophils lysates and particularly with monomeric actin (G-actin).
  • Biofilm development of P. aeruginosa is reduced with:
    - the addition of neutrophils lysates depleted of actin microfilaments (F-actin).
    - the addition of compunds that promotes the depolymerization of F-actin, such as gelsolin or charged poly(amino acids).

Further R&D Required:

Using a state grant to identify the most effective charged poly(amino acids) at disrupting biofilms and testing such compounds on infected contact lenses, and in animal models of eye and skin infections.


Walker et al. Infect. Immun. (2005) 73: 3693-3701.

Parks et. al. Med. Micro. (2009) 58(Pt 4):492-502.

Inventors - J.A. Nick, MD; T.S. Walker; G.S. Worthen, MD; Quinn Parks, PhD

Patent and Licensing Status - Available for licensing.  Published U.S. Patent Application #20060030539; Published U.S. Patent Application #20080207556;  Published U.S. Patent Application #20080199509; International Patent Application # WO 2006/017816.  An additional patent application pending.


For Further Information, Contact:
Emmanuel Hilaire, PhD
Interim Manager
Intellectual Property and Technology Commercialization Program
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: (303) 398-1262
Fax: (303) 270-2352
[email protected]




Support Research at National Jewish Health

David Schwartz, MD, is one of the world's best geneticists, and his work can only happen through your generous support of National Jewish Health.

Learn more and make a donation.

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our A-Z directory of Faculty by Area of Research.